Larimar Therapeutics

Q2 FY2026 EarningsQ2 FY26 results were better than anticipated as net loss of $32.8M beat the consensus mean of -$38.2M, primarily driven by lower-than-expected operating expenses. GAAP EPS of -$0.30 significantly beat the $0.3855 mean estimate, aided by a controlled R&D burn of $28.0M and effective cost management. Critically, the company initiated its rolling BLA for nomlabofusp and maintains a cash runway into Q3 2027, with the first patient dosing in the Phase 3 confirmatory study expected in Q3 2026.